Need a specific person's email?
Browse Arbutus Biopharma Corporation's employee directory (about 45 employees) and reveal verified emails free.
Arbutus Biopharma Corporation's most common email format is FLast@arbutusbio.com (ex. JDoe@arbutusbio.com), used for 66% of arbutusbio.com addresses. Arbutus Biopharma Corporation uses 4 email patterns.
| Format | Example | Share of arbutusbio.com |
|---|---|---|
| FLast@arbutusbio.comMost common | JDoe@arbutusbio.com | |
| First.Last@arbutusbio.com | John.Doe@arbutusbio.com | |
| LFirst@arbutusbio.com | DJohn@arbutusbio.com | |
| FirstLast@arbutusbio.com | JohnDoe@arbutusbio.com |
Browse Arbutus Biopharma Corporation's employee directory (about 45 employees) and reveal verified emails free.
Biotechnology ResearchPennsylvania, United States11-50 Employees
Arbutus Biopharma Corporation is a clinical-stage biotechnology company focused on infectious disease, headquartered in Warminster, Pennsylvania, with a workforce of 11 to 50 employees. It trades on the Nasdaq under the ticker ABUS. The company is developing two lead programs for chronic hepatitis B virus: imdusiran (AB-729), a GalNAc-conjugated RNA interference therapeutic intended for subcutaneous delivery, and AB-101, a proprietary oral PD-L1 inhibitor. In June 2025, Arbutus launched a Scientific Advisory Board comprising leaders in chronic hepatitis B treatment with extensive experience in late-stage clinical trials, and in March 2026 announced a global settlement with Moderna, Inc. that could result in payments of up to $2.5 billion. The company maintains a website at arbutusbio.com and has reported revenue in the range of $10 million to $25 million.
Most common format
FLast@arbutusbio.com
Example: JDoe@arbutusbio.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.